Insights
Insights From Our Experts
Articles
Innovative Approaches to 340B Claims Data Identification
EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research…
Key Considerations When Operationalizing Revenue Management
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’…
Understanding the Inflation Reduction Act: Drug Price Negotiation
Posted by
Denise Woltemath , Brian Abraham on June 16, 20236/16/23
In this second of a series, we explore the details known so far about Medicare drug price negotiation resulting from the implementation of the Inflation Reduction Act. The Centers for Medicare and Medicaid Services (CMS) has…
Digital Guide to Commercializing Complex Therapeutics
Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways,…
Unlocking Success: Exploring Critical Factors for Launching Orphan Drugs
A Conversation with Ashley Cox, Senior Principal, Head of Europe, EVERSANA MANAGEMENT CONSULTING, and Sid Agrawal, Senior Principal, EVERSANA MANAGEMENT CONSULTING Join Ashley Cox, Senior Principal and Head of Europe, and Sid Agrawal, Senior Principal, as…
Informing Optimal Pricing Strategies with a Comprehensive Modeling Approach
Strategically pricing new therapies has always been vitally important for pharmaceutical manufacturers. After the 2022 passing of the historic legislative package, known as the Inflation Reduction Act (IRA), strategic pricing strategies have become especially pivotal. The…
Past and Present U.S. Public Health Laws and Regulations, and Their Impact on the Corresponding FDA Regulated Products and Industries
To be regulated by the FDA, foods, cosmetics, human and animal drugs, biologics, tissues, medical devices, combination products, and tobacco products have to meet the federal public health definitions. This white paper provides an overview of past…
Significance of Promotional and Non-Promotional Materials Review Support Services
Importance of a Well-Defined Medical Legal Regulatory Review Process It is critical for companies to have a well-defined medical, legal and regulatory review process. One of the predominant challenges companies face is that medical and regulatory…
Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services
The number of clinical studies conducted has steadily shown a significant increase year over year for the past two decades. However, the number of new drug and biologic approvals have not seen this same kind of…
The Influx of Generic Launches Leaves Narrow Opportunities for Multiple Sclerosis Access
Since the launch of Sandoz’s Glatopa in June 2015, generic options have slowly entered the multiple sclerosis market, providing some cost relief to payers in this high-cost market. Generic entrants, along with rising costs and a…